Developing osteoclasts and aortic valve organoids for the potential treatment of valve calcification
Abstract
Calcific aortic valve disease (CAVD) is the most frequent valvulopathy in the Western world, butthere is currently no pharmacological treatment to halt or delay the progression of the disease.
Since the only treatment for severe CAVD is valve replacement, there is a need for alternative
therapies. Valve interstitial cells (VICs), especially those in the collagen I rich fibrosa layer, have
been identified as key mediators of valve calcification. Previous studies have developed a 2D
culture model, but this model fails to mimic cell-extracellular matrix and mechanical interactions
known to occur in CAVD. This project addresses the need for a simple 3D model for studying
CAVD and begins to investigate a potential treatment that can be integrated into the model in the
future. Physiological mineral resorbing cells may potentially be used to reduce or eliminate valve
mineralization. The project is divided into two aims: (1) developing and characterizing a 3D fibrosa
model and (2) optimizing and documenting a protocol for generating osteoclasts (OCs) from
human induced pluripotent stem cells (iPSCs). This dissertation outlines the method and initial
characterization of a 3D fibrosa model with confocal microscopy. The differentiation of human
iPSCs to OCs is also described as a potential treatment for valve calcification. Generated OCs or
their exosomes could be combined with the 3D fibrosa model to study novel treatments for valve
calcification.
Description
Thesis (Master's)--University of Washington, 2024
